Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00000556
Recruitment Status : Completed
First Posted : October 28, 1999
Last Update Posted : March 25, 2016
Sponsor:
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)

Brief Summary:
To compare two standard treatment strategies for atrial fibrillation: ventricular rate control and anticoagulation vs. rhythm control and anticoagulation.

Condition or disease Intervention/treatment Phase
Arrhythmia Atrial Fibrillation Cardiovascular Diseases Heart Diseases Drug: amiodarone Drug: sotalol Drug: propafenone Drug: flecainide Drug: quinidine Drug: moricizine Drug: disopyramide Drug: procainamide Drug: adrenergic beta antagonists Drug: verapamil Drug: diltiazem Drug: digoxin Procedure: catheter ablation Device: pacemaker, artificial Phase 3

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Primary Purpose: Treatment
Study Start Date : March 1995
Study Completion Date : September 2002

Resource links provided by the National Library of Medicine






Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   65 Years to 100 Years   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Elderly men and women with atrial fibrillation and other risk factors for stroke.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000556


Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
Layout table for investigator information
OverallOfficial: H. Greene Statistics and Epidemiology Research Corporation (S.E.R.C.)

Study Data/Documents: Individual Participant Data Set  This link exits the ClinicalTrials.gov site
Identifier: AFFIRM
NHLBI provides controlled access to IPD through BioLINCC. Access requires registration, evidence of local IRB approval or certification of exemption from IRB review, and completion of a data use agreement.

Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00000556     History of Changes
Other Study ID Numbers: 100
First Posted: October 28, 1999    Key Record Dates
Last Update Posted: March 25, 2016
Last Verified: November 2005
Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Heart Diseases
Cardiovascular Diseases
Arrhythmias, Cardiac
Pathologic Processes
Quinidine
Digoxin
Amiodarone
Verapamil
Flecainide
Sotalol
Propafenone
Procainamide
Disopyramide
Moricizine
Diltiazem
Adrenergic Agents
Adrenergic beta-Antagonists
Anti-Arrhythmia Agents
Cardiotonic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Vasodilator Agents
Potassium Channel Blockers
Membrane Transport Modulators
Sodium Channel Blockers
Cytochrome P-450 CYP1A2 Inhibitors
Cytochrome P-450 Enzyme Inhibitors